Trial Profile
A Multi-center, Uncontrolled Extension Study Evaluating Efficacy and Safety of SAR153191 in Patients With Active Rheumatoid Arthritis (RA)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Feb 2023
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms EXTEND; RA-EXTEND; SARIL-RA-EXTEND
- Sponsors Sanofi; Sanofi Genzyme
- 02 Feb 2023 Results of two studies ( EXTEND and MONARCH OLE) assessing long-term safety and efficacy of sarilumab in rheumatoid arthritis patients, published in the Rheumatology.
- 22 Nov 2022 Results of pooled analysis from (NCT01061736, NCT02332590, NCT01709578, NCT01146652) assessing disproportionate articular pain prevalence and effects of sarilumab published in the Rheumatology
- 09 Nov 2021 Results assessiing the long-term safety and efficacy of sarilumab in patients with RA using data from two open-label studies: EXTEND (NCT01146652) and MONARCH (NCT02332590) open label extension (OLE) presented at the ACR Convergence 2021